HAVCR2 and glioma: Several reports have evaluated the expression levels of TIM-3 on various immune cell sub-populations comparing expression on cells from glioma/glioblastoma tumor-infiltrating lymphocytes, peripheral blood mononuclear cells (PBMCs) from glioma/glioblastoma patients, and PBMCs from healthy donors.